Trending stocks today
Lorne Steinberg
President & Portfolio Manager at Lorne Steinberg Wealth Management Inc
Member since: Jan '11 · 1808 Opinions
Rating Card
| All | 
Rating
| 
Big Win
| 
Win
| 
Neutral
| 
Loss
| 
Big Loss
|  |
|---|---|---|---|---|---|---|---|
| 4.21 | 160 29.41% | 119 21.88% | 68 12.50% | 119 21.88% | 78 14.34% | ||
| 1 Month | 4.31 | 16 12.12% | 45 34.09% | 37 28.03% | 33 25.00% | 1 0.76% | |
| 6 Months | 4.35 | 32 24.62% | 31 23.85% | 16 12.31% | 35 26.92% | 16 12.31% | |
| 12 Months | 4.08 | 40 33.33% | 20 16.67% | 8 6.67% | 27 22.50% | 25 20.83% | |
| 2 Years | 4.37 | 49 45.37% | 13 12.04% | 6 5.56% | 17 15.74% | 23 21.30% | |
| 5 Years | 3.93 | 23 42.59% | 10 18.52% | 1 1.85% | 7 12.96% | 13 24.07% |
Stock Opinions by Lorne Steinberg
There's value outside North America as the valuation gap between US stocks and ex-US wider than ever. Add to that the strong USD, so those foreign companies are cheap. He likes Japan, UK, and Europe, though many do business in the US. 2025 Canadian outlook: bullish because of further interest rate cuts, and Canada is dividend-driven.
N/A
Unknown
It's cheap at 11x forward PE and pays a 3% dividend. Their vaccine business in China has been hurt, but should recover next year. He's looking at it. Likes their drug pipeline.
It's gone from a market darling to loser, trading at a 10-year low now. It's a show-me stock, though cheap at 15x PE. If the company can grow 5%, maybe it's worth buying. They need to work out some issues first.
Too expensive at a high valuation and doesn't offer enough value. Their Uber Eats succeeded, though, and the company will continue to grow. Management keeps on delivering.
90% of their products are disposable medical supplies. Problem was that during Covid, there were fewer operations, so sales fell and are slowing catching up--8-10% growth annually in the next few years, he thinks. Stock is cheap now, but the stock has done nothing for him. Has excellent prospects.
No, you can never do that. Remember that MFC plunged during 2008 because it got into all kinds of trouble. Today, management has learned a lot from that. He sees big upside in their insurance, US and Asian operations. Still offers decent value and dividend growth. However, insurance companies are prone to serious slides if they make a bad misjudgement.
They carry one mega-drug, so other competitors are already putting out their own weight-loss drug. He prefers Merck for its lower PE and better pipeline--not better, but safer.
Prefers this to BAM, which BN owns as well as many private assets. The CEO holds a lot of stock, too.
He won't add now. The dividend is over 10%; the company says it's safe, but the market disagrees, as shares decline. It may make sense for BCE to cut the dividend to pay down debt, but he's comfortable owning this. It's likely bottoming now, but don't buy it now to collect the dividend for the next 5 years (because it could get cut). No, he doesn't like the US acquisition and hopes management sees value in it.
He doesn't like the sector and he expects natural gas prices to trade off a little. Wait and see with energy as a whole. Nat gas stocks are too high given the nat gas price, and he expects a pullback and opportunities.
Despite buying a bunch of mega-companies, it remains cheaper than 30 years ago. But it has totally failed to deliver shareholder value. The dividend is safe.
Not great over the years, suffering from a bloated infrastructure and lacking focus, like many Japanese companies. It should be split into a few companies.
It was undervalued, forgotten. Management has done a great job. Shares remain cheap as it pays a 4% dividend. Still likes it and would buy it now.
An activist investor is inside the company now. Pays a 3.5% dividend. Not followed that much by Wall Street, but offers decent growth.
The problem is that Gucci continues to underperform; they changed designers. Has huge free cash flow, a good balance sheet and pays a 5.5% dividend. Disappointing.
